Neurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.

Biomarkers of neurodegeneration and neuronal injury have the potential to improve diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy. Neurofilament proteins (NfPs) are ...

Clene (CLNN) has entered into an agreement with German-based APST Research to utilize its extensive NfL database to support ...

While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...

Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkersAPST Research data includes thousands of people living with ALS including ...

Clene (NASDAQ: CLNN) has entered into an agreement with Germany-based APST Research GmbH to utilize its extensive neurofilament light chain (NfL) da ...

The first-ever platform trial for ALS tested four drugs simultaneously, creating a faster path to finding treatments for a ...

Background Neurofilament light chain (NfL) represents a promising biomarker for axonal injury. We present the first exploratory study on serum NfL in patients with a clinically isolated syndrome (CIS) ...

2 German Center for Neurodegenerative Diseases (DZNE), University of Tübingen, Tübingen, Germany NfL levels in CSF differed significantly between FTD, ALS and control subjects (F (2, 109)=88.36, ...

Phosphorylated tau 217 better detected Alzheimer’s disease pathology across a range of neurodegenerative syndromes compared ...

Having access to neurofilament light chain and the ALS Functional Rating Scale-Revised test results is informational to ALS ...